Cathelicidin Peptide Treats Osteoarthritis by Activating AMPK and Reducing Inflammation | Research

The takeaway

Cathelicidin-BF ameliorated osteoarthritis in mice by regulating the AMPK/SIRT1/NF-κB pathway, reducing joint inflammation and cartilage damage.

AMPK/SIRT1 activated
Cathelicidin-BF peptide activates metabolic energy sensing and longevity pathways to protect joints from osteoarthritis

What the researchers found

Cathelicidin-BF ameliorated osteoarthritis by activating AMPK/SIRT1 and inhibiting NF-κB, reducing joint inflammation and cartilage damage in a murine OA model.

Why it matters

Osteoarthritis has no disease-modifying treatment. A natural antimicrobial peptide that reduces joint inflammation through a metabolic pathway (AMPK/SIRT1) could lead to new OA therapies.

The numbers in context

BF-30 activated the AMPK/SIRT1 pathway and inhibited NF-κB in both cell culture and animal OA models.

How the study worked

Mouse osteoarthritis model treated with cathelicidin-BF. Assessed joint pathology, inflammatory markers, and AMPK/SIRT1/NF-κB pathway components.

Who was studied

OA chondrocytes and animal OA models treated with cathelicidin-BF (BF-30)

What this study cannot tell us

Mouse OA model may not fully replicate human disease. Cathelicidin-BF is snake-derived and would need modification for human use. Optimal dosing and delivery route for joint protection not established.

How to read the evidence

Preliminary evidence: mouse OA model with clear mechanistic pathway identification. No human joint data.

When this study was published

Published in 2024. Expands cathelicidin applications from antimicrobial to anti-inflammatory joint protection.

The bigger picture

Cathelicidins are best known as antimicrobial peptides, but their anti-inflammatory properties are increasingly recognized. Finding that cathelicidin-BF treats OA through the same AMPK/SIRT1 pathway linked to longevity and metabolic health suggests these peptides have broader therapeutic potential than previously appreciated.

Questions still open

Could cathelicidin-BF be developed as a local joint injection for OA?
Do other cathelicidin family members share these anti-OA properties?
Is the AMPK/SIRT1 pathway a viable target for OA drug development?

Common questions

What is cathelicidin-BF?

Cathelicidin-BF is an antimicrobial peptide originally found in banded krait snake venom. While primarily studied for its germ-killing ability, this study reveals it also has powerful anti-inflammatory effects that can protect joints from osteoarthritis.

How does it help osteoarthritis?

Cathelicidin-BF activates the AMPK/SIRT1 pathway — a cellular energy-sensing and stress-resistance system — while blocking NF-κB inflammatory signaling. This reduces the chronic inflammation that drives cartilage destruction in osteoarthritis.

Read the original research

Cathelicidin-BF regulates the AMPK/SIRT1/NF-κB pathway to ameliorate murine osteoarthritis: In vitro and in vivo studie.

International immunopharmacology, 134, 112201

View on PubMed ↗Publisher’s paper ↗

Citation

Zhou, Hao; Zou, Linfang; Ren, Hui; Shen, Zhenyu; Lin, Yuanqu; Cai, Haikang; Zhang, Jingdong. (2024). Cathelicidin-BF regulates the AMPK/SIRT1/NF-κB pathway to ameliorate murine osteoarthritis: In vitro and in vivo studie.. International immunopharmacology, 134, 112201. https://doi.org/10.1016/j.intimp.2024.112201